Sacrococcygeal teratoma laboratory tests

Sacrococcygeal teratoma Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Sacrococcygeal teratoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sacrococcygeal teratoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sacrococcygeal teratoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sacrococcygeal teratoma laboratory tests
CDC on Sacrococcygeal teratoma laboratory tests
Sacrococcygeal teratoma laboratory tests in the news
Blogs on Sacrococcygeal teratoma laboratory tests
Directions to Hospitals Treating Sacrococcygeal teratoma
Risk calculators and risk factors for Sacrococcygeal teratoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Overview

Alpha-fetoprotein and beta-hCG should be evaluated in patients with sacrococcygeal teratoma to determine the presence of malignant component of the tumor.

Laboratory Findings

• Alpha-fetoprotein
• Beta-hCG